Barracuda Networks (CUDA) Delivers Above-Consensus Profit; Roka Bioscience (ROKA) Takes Upward-Bounce


Shares of Barracuda Networks Inc. (NYSE:CUDA) climbed over 7% in after-hours trading Monday as the company delivered in its financial results quarterly profit and revenue numbers that surpassed Wall Street analysts’ expectations.

For its third quarter fiscal 2017, Barracuda posted revenue of $88.8 million, an 10.9% increase year over year, and non-GAAP net income of $11.64 million, or $0.22 per diluted share, compared to non-GAAP net income of $3.98 million, or $0.07 per diluted share, topping the Capital IQ Consensus Estimate of $0.14 earnings per share on revenues of $86.6 million for the period

CUDA stock finished the regular session in positive territory by 4.35% ( or +$0.99) at $23.77 with a total volume of 1.95M shares traded.

Barracuda Networks, which provides cloud-enabled security and data protection solution, has 52.30M shares outstanding, market capitalization (intraday) of $1.24B and CUDA stock one-year range is between $9.44 and $26.69 per share.



Roka Bioscience, Inc. (Nasdaq:ROKA) stock surged 6.99% (or +$0.32) to close at $4.90 on Monday and continued the upward trajectory in after-hours trade, gaining more than 15% in the extended session on no particular news from the molecular diagnostics company that may explain this movement in the stock.

441,203 shares of the molecular diagnostics company changed hands during the day, representing a large increase in activity versus its average volume of 90,620 shares.

Roka Bioscience, which focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens, has 1.84M shares outstanding, market capitalization (intraday) of $9.39M and ROKA stock 52-week range is from $3.66 to $16.00 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at